Boosting revenue through increased advertising, sweeping job cuts, and the ability to pay for a blue verified badge are some of ... including Pfizer, GSK, and Novo Nordisk. On 14 November, Eli ...
GSK is paying $80 million to ink a multi-target neurodegenerative pact with Flagship-founded Vesalius Therapeutics that ...
Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...
GSK is the latest to turn its back on prominent industry lobbying group Biotechnology Innovation Organization (BIO), ...
GSK Plc agreed on a partnership deal worth as much as $650 million with US biotech Vesalius Therapeutics to help advance drug ...
GSK’s Trelegy, a treatment for chronic obstructive pulmonary disease (COPD), aimed to address a gap in the market with its ...
Despite the rise of a vaccine skeptic in the campaign of US presidential election winner Donald Trump, GSK CEO Emma Walmsley ...
The print ads featured a prominent display of a person’s back, highlighting where shingles rashes typically emerge.
GSK's new long-acting drug candidate for severe asthma, depemokimab, reduced the rate of severe attacks by 54% in a pair of phase 3 trials presented at the European Respiratory Society (ERS ...
The three big airports that serve New York City have proposed allowing concession prices to rise and adding a surcharge to cover higher wages and improved worker benefits. By Patrick McGeehan ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback